PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity

Combination of dual mTORC1/2 inhibition and immune-checkpoint blockade potentiates anti-tumour immunity

(2018) Sophie Langdon et al.   OncoImmunology

Salmon provides fast and bias-aware quantification of transcript expression

(2017) Rob Patro et al.   NATURE METHODS

Inference of immune cell composition on the expression profiles of mouse tissue

(2017) Ziyi Chen et al.   Scientific Reports

PI3Kδ Inhibition Enhances the Antitumor Fitness of Adoptively Transferred CD8+ T Cells

(2017) Jacob S. Bowers et al.   Frontiers in Immunology

PI3K Inhibition Reduces Mammary Tumor Growth and Facilitates Antitumor Immunity and Anti-PD1 Responses

(2016) Jiqing Sai et al.   CLINICAL CANCER RESEARCH

Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3K  and PI3K , Demonstrates Treatment Strategies for PIK3CA-Dependent Breast Cancers

(2016) K. Hudson et al.   MOLECULAR CANCER THERAPEUTICS

PI3Kγ is a molecular switch that controls immune suppression

(2016) Megan M. Kaneda et al.   NATURE

Targeting PI3K in Cancer: Impact on Tumor Cells, Their Protective Stroma, Angiogenesis, and Immunotherapy

(2016) K. Okkenhaug et al.   Cancer Discovery

Rational Selection of Syngeneic Preclinical Tumor Models for Immunotherapeutic Drug Discovery

(2016) Suzanne I.S. Mosely et al.   Cancer Immunology Research

Molecular and Genetic Properties of Tumors Associated with Local Immune Cytolytic Activity

(2015) Michael S. Rooney et al.   CELL

PI3K inhibitors in inflammation, autoimmunity and cancer

(2015) Anne-Katrien Stark et al.   CURRENT OPINION IN PHARMACOLOGY

HISAT: a fast spliced aligner with low memory requirements

(2015) Daehwan Kim et al.   NATURE METHODS

Robust enumeration of cell subsets from tissue expression profiles

(2015) Aaron M Newman et al.   NATURE METHODS

Akt1 and -2 inhibition diminishes terminal differentiation and enhances central memory CD8+T-cell proliferation and survival

(2015) Rasha Abu Eid et al.   OncoImmunology

Inhibition of Akt signaling promotes the generation of superior tumor-reactive T cells for adoptive immunotherapy

(2014) A. B. van der Waart et al.   BLOOD

Akt Inhibition Enhances Expansion of Potent Tumor-Specific Lymphocytes with Memory Cell Characteristics

(2014) J. G. Crompton et al.   CANCER RESEARCH

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

(2014) Khaled Ali et al.   NATURE

The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis

(2014) S. Blankley et al.   PHILOSOPHICAL TRANSACTIONS OF THE ROYAL SOCIETY B-BIOLOGICAL SCIENCES

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

(2014) K. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective Inhibition of Regulatory T Cells by Targeting the PI3K-Akt Pathway

(2014) R. Abu-Eid et al.   Cancer Immunology Research

Causal analysis approaches in Ingenuity Pathway Analysis

(2013) Andreas Krämer et al.   BIOINFORMATICS

GSVA: gene set variation analysis for microarray and RNA-Seq data

(2013) Sonja Hänzelmann et al.   BMC BIOINFORMATICS

The Long-Term Survival Potential of Mature T Lymphocytes Is Programmed During Development in the Thymus

(2011) C. Sinclair et al.   Science Signaling

PI3K  Inhibitors in Cancer: Rationale and Serendipity Merge in the Clinic

(2011) D. A. Fruman et al.   Cancer Discovery

PI3K p110  regulates T-cell cytokine production during primary and secondary immune responses in mice and humans

(2010) D. R. Soond et al.   BLOOD

Differential expression analysis for sequence count data

(2010) Simon Anders et al.   GENOME BIOLOGY